Korhan Kilic

Dr. Korhan Kilic

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2012 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
HUHulya Uzkeser
Hulya Uzkeser
KYKadir Yildirim
Kadir Yildirim
BABulent Aktan
Bulent Aktan
SKSaliha Karatay
Saliha Karatay
HKHasan Kaynar
Hasan Kaynar
KKKorhan Kilic
Korhan Kilic

7 April 2018 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
KKKorhan Kilic
Korhan Kilic
MSMuhammed Sedat Sakat
Muhammed Sedat Sakat
FAFazile Nur Ekinci Akdemir
Fazile Nur Ekinci Akdemir
SYSerkan YILDIRIM
Serkan YILDIRIM
YSYavuz Selim Saglam
Yavuz Selim Saglam
SASeda Askin
Seda Askin
Cisplatin is an antineoplastic agent widely used in the treatment of a variety of cancers. Ototoxicity is one of the main side-effects restricting the use of cisplatin. The purpose of this study was to investigate the protective efficacy of gallic acid, in biochemical, functional and histopathological terms, against ototoxicity induced by cisplatin. Twenty-eight female Sprague Dawley rats were included. Rats were randomly assigned into four groups of seven animals each. Cisplatin group received a single intraperitoneal dose of 15mg/kg cisplatin. Gallic acid group received intraperitoneal gallic acid at 100mg/kg for five consecutive days. Cisplatin+gallic acid group received intraperitoneal gallic acid at 100mg/kg for five consecutive days and a single intraperitoneal dose of 15mg/kg cisplatin at 3rd day. A control group received 1mL intraperitoneal saline solution for five consecutive days. Prior to drug administration, all rats were exposed to the distortion product otoacoustic emissions test. The test was repeated on the 6th day of the study. All rats were then sacrificed; the cochleas were removed and set aside for biochemical and histopathological analyses. In cisplatin group, Day 6 signal noise ratio values were significantly lower than those of the other groups. Also, malondialdehyde levels in cochlear tissues were significantly higher, superoxide dismutase and glutathione peroxidase activities were significantly lower compared to the control group. Histopathologic evaluation revealed erosion in the stria vascularis, degeneration and edema in the connective tissue layer in endothelial cells, impairment of outer hair cells and a decrease in the number of these calls. In the cisplatin+gallic acid group, this biochemical, histopathological and functional changes were reversed. In the light of our findings, we think that gallic acid may have played a protective role against cisplatin-induced ototoxicity in rats, as indicated by the distortion product otoacoustic emissions test results, biochemical findings and immunohistochemical analyses.

28 November 2018 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
KKKorhan Kilic
Korhan Kilic
MSMuhammed Sedat Sakat
Muhammed Sedat Sakat
SYSerkan Yildirim
Serkan Yildirim
FKFatih Mehmet Kandemir
Fatih Mehmet Kandemir
MGMustafa Sitki Gozeler
Mustafa Sitki Gozeler
SKSefa Kucukler
Sefa Kucukler

7 August 2018 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
MSMuhammed Sedat Sakat
Muhammed Sedat Sakat
KKKorhan Kilic
Korhan Kilic
FAFazile Nur Ekinci Akdemir
Fazile Nur Ekinci Akdemir
SYSerkan YILDIRIM
Serkan YILDIRIM
GEGizem Eser
Gizem Eser
AKAhmet Kiziltunc
Ahmet Kiziltunc
Ototoxicity refers to cellular damage or function impairment developing in the inner ear in association with any therapeutic agent or chemical substance, and still represents the principal side-effect restricting the use of cisplatin. The aim of this study was to perform a biochemical, functional and histopathological investigation of the potential protective effect of eugenol against cisplatin-induced ototoxicity. The study was performed with 24 female Sprague Dawley rats. Distortion product otoacoustic emissions tests were performed on all animals, which were randomized into four equal groups. A single intraperitoneal dose of 15mg/kg cisplatin was administered to cisplatin group, while the eugenol group received 100mg/kg eugenol intraperitoneal for five consecutive days. 100mg/kg eugenol was administered to cisplatin+eugenol group for 5 days. On the third day, these rats were received a single dose of 15mg/kg cisplatin. The control group was given 8mL/kg/day intraperitoneal saline solution for five days. The distortion product otoacoustic emissions test was repeated 24h after the final drug administration. All animals were sacrificed, and the cochleas were subsequently used for biochemical and histopathological examinations. Cisplatin caused oxidative stress in the cochlea, impaired the cochlear structure and significantly reduced signal noise ratio levels. Administration of eugenol together with cisplatin reversed these effects and provided functional, biochemical and histopathological protection. The study findings represent the first indication in the literature that eugenol may protect against ototoxicity by raising levels of antioxidant enzymes and lowering those of oxidant parameters.

1 November 2018 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
MGMustafa Sitki Gozeler
Mustafa Sitki Gozeler
MSMuhammed Sedat Sakat
Muhammed Sedat Sakat
KKKorhan Kilic
Korhan Kilic
OOOzgur Ozmen
Ozgur Ozmen
ACAbdullah Can
Abdullah Can
IIIlker Ince
Ilker Ince

16 February 2016 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
MSMuhammed Sedat Sakat
Muhammed Sedat Sakat
KKKorhan Kilic
Korhan Kilic
SBSami Bercin
Sami Bercin